Protocol Ledger

NCT05219435 · Phase II · COMPLETED

Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Interventional Phase II clinical trial protocol NCT05219435 sponsored by Spanish Oncology Genito-Urinary Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-06 Enrollment: 25 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05219435
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)25 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05219435
Protocol FieldVerified Registry Value
NCT IdentifierNCT05219435
Consolidated Lead SponsorSpanish Oncology Genito-Urinary Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment25 participants (ACTUAL)
Registered Start Date2022-07-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05219435
Hospital Research SiteLocationSite Profile
Hospital Clínic de BarcelonaBarcelona, SpainOpen Hospital Dossier ->
Hospital Universitario Ramón y CajalMadrid, SpainOpen Hospital Dossier ->
Hospital Universitario 12 de OctubreMadrid, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI